Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Volume: 123, Issue: 6, Pages: 1351 - 1359
Published: Jun 1, 2016
Abstract
Purpose null To provide 2-year results comparing anti–vascular endothelial growth factor (VEGF) agents for center-involved diabetic macular edema (DME) using a standardized follow-up and retreatment regimen. null Design null Randomized clinical trial. null Participants null Six hundred sixty participants with visual acuity (VA) impairment from DME. null Methods null Randomization to 2.0-mg aflibercept, 1.25-mg repackaged (compounded)...
Paper Details
Title
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Published Date
Jun 1, 2016
Volume
123
Issue
6
Pages
1351 - 1359
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.